A Phase 3 Open-Label Randomized Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Malignant Pleural Mesothelioma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Has a confirmed histological diagnosis of MPM with histological type epithelioid or biphasic (predominantly [>50%] epithelioid). Histological diagnosis of MPM will be confirmed centrally using specimens or slides from tumor specimens obtained at the time of initial presentation or a subsequent procedure. 2) Has failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, which may have been chemotherapeutic and/or immunotherapeutic treatment regimens for MPM which included at least 1 anti-folate and platinum combination regimen. Patients who have undergone primary surgical resection and/or radiation therapy to the pulmonary site are eligible to participate.

You may not be eligible for this study if the following are true:

  • 1) Is "treatment-naïve" (i.e., has not received at least 1 anti-folate and platinum combination regimen). 2) Has previously received 3 or more lines of systemic chemotherapeutic or immunotherapeutic treatment. 3) Has previously received treatment with gemcitabine. 4) Has stage IV extrathoracic metastatic disease.
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.